Lifeward shares surge 35.42% after-hours after Humana approves ReWalk 7 exoskeleton reimbursement.

Lifeward (LFWD) surged 35.42% in after-hours trading following the announcement that its ReWalk 7 Personal Exoskeleton received prior authorization from Humana Medicare Advantage Plan, the second-largest U.S. Medicare Advantage provider. This approval, alongside UnitedHealthcare’s earlier authorization, covers 47% of Medicare Advantage enrollees, significantly expanding access to the exoskeleton for spinal cord injury patients. The move is expected to strengthen Lifeward’s revenue and cash flow dynamics by enhancing reimbursement predictability and scalability. CEO Mark Grant highlighted the milestone as a critical step in payer adoption, signaling growing recognition of the technology’s clinical value. The approval aligns with CMS’s 2024 formal reimbursement pathway for exoskeletons, accelerating Lifeward’s market expansion and reinforcing investor confidence in its growth trajectory.